Melanoma and MYC-driven lymphoma cells exhibit high levels of replication stress and show excellent sensitivity to Chk1 inhibitors in vitro, suggesting that these cancer types might be suitable candidates for testing the efficacy of single agent treatment in vivo [29,30]. The gene discussed is CHEK1; the disease is melanoma.